GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing innovative immuno-oncology therapies designed to harness the power of the body’s immune system to fight cancer. The company’s research is centered on its proprietary TriKE® (Tri-specific Killer Engager) platform, which activates and enhances the cancer-killing activity of natural killer (NK) immune cells. The TriKE® platform is engineered to stimulate NK cell proliferation and direct targeted immune responses against tumor cells. GT Biopharma holds an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies based on this technology, advancing a pipeline of next-generation immunotherapies aimed at improving treatment outcomes for patients with cancer.
Market Chart
Industry Insights
Biotechnology companies listed on the Nasdaq exchange represent a critical segment of the global life sciences industry. These firms focus on developing new therapeutics, diagnostics, and advanced biomedical technologies aimed at addressing major health challenges.
The biotechnology sector continues to attract institutional capital due to its potential for breakthrough medical innovations and long-term growth driven by scientific advancements in immunotherapy, precision medicine, and next-generation biologics.
Industry Stocks
Bristol Myers Squibb BMY
Global biopharmaceutical leader with major immuno-oncology therapies including Opdivo and Yervoy.
Merck & Co. MRK
Developer of Keytruda, one of the world’s leading cancer immunotherapy treatments.
Gilead Sciences GILD
Biopharmaceutical company advancing cell therapies and oncology treatments through Kite Pharma.
Regeneron Pharmaceuticals REGN
Biotechnology innovator developing antibody-based cancer therapies and immune system treatments.
Spotrate Market News
Market News
Disclosure & Disclaimer
Spotrate may receive compensation from companies featured on this page for investor communications, media production, or news distribution services. Any such relationships will be disclosed accordingly.
Content published by Spotrate is provided for informational purposes only and should not be construed as investment advice or a recommendation to buy or sell securities. All investing involves risk, including the possible loss of principal.